🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to my deserving husband Daniel Gorovets on becoming associate program director of Memorial Sloan Kettering Radiation Oncology !

Congrats to Debyani Chakravarty, PhD 🇺🇦 Niki Schultz David B. Solit, MD and everyone involved! OncoKB is a game changer for patients, clinicians, and trials. It’s impossible to fully appreciate the impact it has on patient care. I reference it multiple times a day👩🏽‍💻Thanks for this incredible resource!

🔎Do you know the symptoms of #UterineCancer? Dr. Alison Schram discusses common symptoms with @healthmagazine. This collaborative article also features Pamela T. Soliman MD (MD Anderson Cancer Center) & @DrMatulonis (Dana-Farber)! @sloan_kettering #gyncsm #gyncancer health.com/condition/uter…

Game changing for our patients. Congrats #VickyMakker @sloan_kettering and everyone involved!

Thrilled to share MSKs preclinical and initial clinical experience with Zeno which led to the ongoing eNRGy study. Treating these pts has been a highlight of my career. Grateful to have incredible lab collaborators and be at @sloan_kettering where anything is possible.

Zenocutuzumab, a #HER2 x #HER3 #bispecific antibody, is effective therapy for tumors driven by #NRG1 gene rearrangements by Alison Schram, @Odintsov_I, Romel Somwar, and colleagues @sloan_kettering. bit.ly/34K4zJJ

Great read 👇🏻@DrEzraRosen

Despite having lost her voice, Hilla Solomon told us all about her group's research on possible #EndometrialCancer treatment options that led to a #ClinicalTrial at MSK. Revolution Medicine Radha Mukherjee Alison Schram #AACR22

Grateful to be involved in this exciting study demonstrating efficacy targeting the elusive p53 (Y220C). Cool biology and helping patients!

In case you missed it, updated results from the eNRGy study presented at #ASCO22! Zeno ORR of 34% (27/79) across tumor types & 42% (8/19) in PDAC. Median DOR of 9.1 mo and extremely well tolerated. Zeno has the potential to become new SOC for this unmet clinical need.

🎯On behalf of all co-investigators presenting👉Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a novel cfDNA algorithm for treatment w RLY-4008, a highly selective irreversible FGFR2 inhibitor #ENAsymp22 Alison Schram OncoAlert Relay Therapeutics

We are pleased to announce our manuscript on pan-cancer multi-PIK3CA mutations, published this week in Clinical Cancer Research. x.com/smruthy90/stat…

Well deserved! Tina Jost I hope you continue this great work on the mechanism of radiosensitization and most effective use of DDR therapies

Don't miss Alison Schram explaining class II and III BRAF alterations. hmpgloballearningnetwork.com/site/onc/video…

⭐️Mark your calendars if you are attending the triple meeting 👉 Super thrilled to be discussing about the "Future of Tissue-Agnostic Drug Development" with an amazing panel of speakers at the AACR-NCI-EORTC AACR National Cancer Institute EORTC #Targets23 Boston #PrecisionMedicine Alison Schram

Fun session thanks to Vivek Subbiah, MD, Christophe Le Tourneau, and Jordi Rodon complete with a sonnet about tumor agnostic drug development by ChatGPT/Vivek! 🎯🧬💊😂

I second this. Pat you are a powerhouse, role model, mentor, brilliant trialist and compassionate doctor. AACR is in the best hands. Congrats! AACR President Lillian L. Siu

I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! Annals of Oncology ESMO - Eur. Oncology Vivek Subbiah, MD Juliana Beal, MD G Curigliano MD PhD Razelle Kurzrock, MD Sewanti Limaye 🇮🇳🇺🇸 Stefan Michiels Joaquin Mateo Niamh Coleman, MD PhD FabriceAndre @ElenaGarralda

#ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion! Catch this all-new episode of #LungCancerConsidered as Stephen V Liu, MD and Alison Schram discuss this breakthrough and what this approval means for treating NSCLC patients with an NRG1 fusion. 🔗 Listen

Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led to recent FDA approval in lung and pancreatic cancer. RNA seq is critical to identify these fusions. 🧬NEJM pubmed.ncbi.nlm.nih.gov/39908431/